Recent reports in The Atlantic suggest that the science behind Ozempic and other GLP-1 drugs may be misunderstood, as the weight-loss effects appear to be driven by the brain rather than the gut. These drugs cross the blood-brain barrier and may affect addictive behaviors, though scientists admit they do not fully understand the long-term consequences. Despite this, prescriptions have increased 400% since 2019, with the industry projected to reach $100 billion by 2030.
